Camurus

Camurus Liabilities

The The Liabilities of Camurus (CAMX.ST) as of Nov 4, 2026 is 504.56 M SEK. In the previous year, The Liabilities was 467.33 M SEK — a change of 7.97% (higher).

Liabilities

504.56 MSEK

YoY

7.97%

Last updated:

In 2025, Camurus's total liabilities amounted to 504.56 M SEK, a 7.97% difference from the 467.33 M SEK total liabilities in the previous year.

The Camurus Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
112.40 M SEK
Jan 1, 2019
140.41 M SEK
Jan 1, 2020
196.66 M SEK
Jan 1, 2021
232.99 M SEK
Jan 1, 2022
301.80 M SEK
Jan 1, 2023
414.82 M SEK
Jan 1, 2024
467.33 M SEK
Jan 1, 2025
504.56 M SEK
The Camurus Liabilities history
YEARLiabilitiesYoY
504.56 MSEK+7.97%
467.33 MSEK+12.66%
414.82 MSEK+37.45%
301.80 MSEK+29.53%
232.99 MSEK+18.47%
196.66 MSEK+40.06%
140.41 MSEK+24.92%
112.40 MSEK+23.61%
90.93 MSEK+20.67%
75.36 MSEK-57.13%
175.79 MSEK+108.75%
84.21 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Camurus Stock analysis

What does Camurus do? Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Camurus's Liabilities

Camurus's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Camurus's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Camurus's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Camurus's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Camurus’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Camurus stock

The Liabilities of Camurus is 504.56 M SEK in 2025.

The Liabilities of Camurus changed from 467.33 M SEK to 504.56 M SEK, representing a 7.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Camurus since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Camurus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Camurus

All Key Metrics — Camurus